Mototsugu Oya

17.0k total citations · 1 hit paper
622 papers, 11.2k citations indexed

About

Mototsugu Oya is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Mototsugu Oya has authored 622 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 317 papers in Pulmonary and Respiratory Medicine, 216 papers in Surgery and 169 papers in Molecular Biology. Recurrent topics in Mototsugu Oya's work include Bladder and Urothelial Cancer Treatments (140 papers), Renal cell carcinoma treatment (132 papers) and Prostate Cancer Treatment and Research (130 papers). Mototsugu Oya is often cited by papers focused on Bladder and Urothelial Cancer Treatments (140 papers), Renal cell carcinoma treatment (132 papers) and Prostate Cancer Treatment and Research (130 papers). Mototsugu Oya collaborates with scholars based in Japan, United States and Germany. Mototsugu Oya's co-authors include Eiji Kikuchi, Takeo Kosaka, Akira Miyajima, Masaru Murai, Shuji Mikami, Ryuichi Mizuno, Ken Nakagawa, Takashi Ohigashi, Ken Marumo and Kazuhiro Matsumoto and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mototsugu Oya

590 papers receiving 11.0k citations

Hit Papers

Olaparib plus abiraterone versus placebo plus abiraterone... 2023 2026 2024 2025 2023 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
    2023 132 citations Fred Saad, Noel W. Clarke et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mototsugu Oya Japan 50 4.5k 3.8k 3.4k 3.2k 1.9k 622 11.2k
Hideaki Miyake Japan 49 4.7k 1.0× 4.0k 1.0× 2.7k 0.8× 3.2k 1.0× 2.1k 1.1× 620 10.8k
Norio Nonomura Japan 49 3.6k 0.8× 4.6k 1.2× 2.3k 0.7× 2.4k 0.7× 1.8k 1.0× 598 11.4k
David I. Quinn United States 59 4.8k 1.1× 4.0k 1.0× 4.5k 1.3× 5.8k 1.8× 2.3k 1.2× 420 14.1k
Howard L. Parnes United States 46 6.6k 1.5× 2.0k 0.5× 1.5k 0.5× 2.3k 0.7× 1.5k 0.8× 205 10.9k
Wael Sakr United States 56 5.2k 1.2× 3.1k 0.8× 2.9k 0.9× 3.0k 0.9× 2.2k 1.2× 214 11.4k
Armen Aprikian Canada 48 4.2k 0.9× 2.2k 0.6× 3.0k 0.9× 2.0k 0.6× 1.4k 0.7× 279 8.7k
Christopher P. Evans United States 58 4.9k 1.1× 5.1k 1.3× 1.1k 0.3× 1.8k 0.6× 3.6k 1.9× 250 10.3k
Joel B. Nelson United States 49 6.0k 1.3× 3.5k 0.9× 1.4k 0.4× 3.0k 0.9× 1.8k 0.9× 188 10.8k
Akihiro Ito Japan 52 2.5k 0.5× 3.2k 0.8× 3.7k 1.1× 2.9k 0.9× 785 0.4× 541 10.5k
David G. McLeod United States 61 9.7k 2.2× 3.0k 0.8× 1.9k 0.6× 2.5k 0.8× 2.4k 1.3× 271 13.3k

Countries citing papers authored by Mototsugu Oya

Since Specialization
Citations

This map shows the geographic impact of Mototsugu Oya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mototsugu Oya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mototsugu Oya more than expected).

Fields of papers citing papers by Mototsugu Oya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mototsugu Oya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mototsugu Oya. The network helps show where Mototsugu Oya may publish in the future.

Co-authorship network of co-authors of Mototsugu Oya

This figure shows the co-authorship network connecting the top 25 collaborators of Mototsugu Oya. A scholar is included among the top collaborators of Mototsugu Oya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mototsugu Oya. Mototsugu Oya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Adetutu, Adewale, et al.. (2024). Typhoid fever and medicinal plants review: A case study in Nigeria. 4(2). 22–48. 1 indexed citations
2.
3.
Shigeta, Keisuke, Masanori Hasegawa, Takako Hishiki, et al.. (2023). IDH2 stabilizes HIF ‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. The EMBO Journal. 42(4). e110620–e110620. 49 indexed citations
4.
Osawa, Takahiro, Mototsugu Oya, Tohru Okanishi, et al.. (2023). Clinical Practice Guidelines for tuberous sclerosis complex‐associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update. International Journal of Urology. 30(10). 808–817. 4 indexed citations
5.
Takeda, Toshikazu, Yota Yasumizu, Nobuyuki Tanaka, et al.. (2023). Predictors of urinary function recovery after laparoscopic and robot-assisted radical prostatectomy. International braz j urol. 49(1). 50–60. 4 indexed citations
6.
Saito, Takafumi, Kent Kanao, Takayuki Takahashi, et al.. (2023). New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma. SHILAP Revista de lepidopterología. 5(2). 281–288. 1 indexed citations
7.
Umakoshi, Hironobu, Tsugio Seki, Celso E. Gómez-Sánchez, et al.. (2022). Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution. The Journal of Clinical Endocrinology & Metabolism. 107(9). 2439–2448. 13 indexed citations
8.
Hagiwara, Masayuki, Yota Yasumizu, Nami Yamashita, et al.. (2020). MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. Cancer Research. 81(4). 1111–1122. 62 indexed citations
9.
Ide, Hiroki, Satoshi Inoue, Taichi Mizushima, et al.. (2018). Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer. Molecular Cancer Therapeutics. 17(7). 1566–1574. 19 indexed citations
10.
Tatsugami, Katsunori, Mototsugu Oya, Koki Kabu, & Hideyuki Akaza. (2018). Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis. British Journal of Cancer. 119(2). 241–247. 10 indexed citations
11.
12.
Miyazaki, Yasumasa, Takeo Kosaka, Shuji Mikami, et al.. (2012). The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma. Clinical Cancer Research. 18(15). 4145–4153. 38 indexed citations
13.
Nishimoto, Koshiro, Ken Nakagawa, Dan Li, et al.. (2010). Adrenocortical Zonation in Humans under Normal and Pathological Conditions. The Journal of Clinical Endocrinology & Metabolism. 95(5). 2296–2305. 237 indexed citations
14.
15.
Matsushima, Masashi, Eiji Kikuchi, Masanori Hasegawa, et al.. (2010). Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study. BMC Urology. 10(1). 12–12. 9 indexed citations
16.
Ide, Hiroki, Jun Nakashima, Eiji Kikuchi, et al.. (2009). Prognostic Stratification in Patients Who Received Hormonal Therapy for Prostate-specific Antigen Recurrence after Radical Prostatectomy. Japanese Journal of Clinical Oncology. 40(2). 177–180. 3 indexed citations
17.
Kikuchi, Eiji, Vitaly Margulis, Pierre I. Karakiewicz, et al.. (2008). Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology. 27(4). 612–618. 215 indexed citations
18.
19.
Oya, Mototsugu, Shuji Mikami, Ryuichi Mizuno, et al.. (2004). Differential expression of activator protein-2 isoforms in renal cell carcinoma. Urology. 64(1). 162–167. 10 indexed citations
20.
Oya, Mototsugu, Atsushi Takayanagi, Akio Horiguchi, et al.. (2003). Increased nuclear factor-κB activation is related to the tumor development of renal cell carcinoma. Carcinogenesis. 24(3). 377–384. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideaki Miyake Breakdown of academic impact, for papers by Norio Nonomura Breakdown of academic impact, for papers by David I. Quinn Breakdown of academic impact, for papers by Howard L. Parnes Breakdown of academic impact, for papers by Wael Sakr Breakdown of academic impact, for papers by Armen Aprikian Breakdown of academic impact, for papers by Christopher P. Evans Breakdown of academic impact, for papers by Joel B. Nelson Breakdown of academic impact, for papers by Akihiro Ito Breakdown of academic impact, for papers by David G. McLeod
Rankless by CCL
2026